Traditional CAR-T treatments, while successful in some blood cancer cases, have faced limitations due to their complexity, expense, and time-consuming nature. The Johns Hopkins team’s innovative approach circumvents this by delivering a nanotechnological payload that automatically activates and modifies T cells—the warriors of the immune system—in vivo. This breakthrough has the potential to democratize access to life-saving immunotherapies and dramatically streamline treatment protocols, reducing barriers posed by existing methodologies.

The core of these nanoparticles is formed from biodegradable polymers composed of ester units, which safely degrade within aqueous environments such as the bloodstream. The surface of each nanoparticle is meticulously functionalized with two antibodies: antiCD3 and antiCD28. These critical molecules serve as homing devices, enabling the nanoparticles to precisely locate and bind to T cells scattered throughout the blood and lymphoid tissues. Upon engagement, the nanoparticles not only stimulate T cell activation but also facilitate internalization, which is pivotal for subsequent genetic reprogramming.

Encased within the molecular shell of these “ship-like” nanoparticles lies messenger RNA (mRNA) – a transient genetic blueprint that instructs T cells to express receptors specifically designed to detect and eliminate B cells that contribute to diseases like lupus, leukemia, and lymphoma. By delivering mRNA payloads directly inside T cells, the nanoparticles roundly bypass the challenges of cellular engineering outside the body, enabling an internal transformation of immune cells into potent, disease-targeting agents.

In rigorous preclinical trials involving healthy murine models, a single injection of these nanoparticles resulted in a staggering 95% reduction of circulating B cells within just 24 hours. Furthermore, approximately half of the B cells residing in the spleen were depleted, showcasing the nanoparticles’ systemic reach and effective targeting capabilities. Remarkably, even after a week, blood B cells remained suppressed at about 50% of their original levels, illustrating a potent yet controlled immune modulation.

The stepwise operational mechanism of these nanoparticles is as ingenious as it is elegant. Comparable to multi-stage rockets designed for outer space missions, these engineered carriers embark on an “inner space” voyage, first engaging and activating target T cells, then penetrating cellular membranes, and finally degrading to unleash mRNA cargoes. This programmed release not only ensures successful mRNA transfer but also prevents unintended degradation, an obstacle that commonly hinders intracellular delivery vehicles.

Delivering genetic material specifically to T cells presents unique challenges, as these cells possess intrinsic defenses to resist uptake and neutralize foreign particles—a feature evolved to prevent viral hijacking such as seen in HIV infections. The Johns Hopkins team overcame this biological defense by optimizing nanoparticle composition and surface chemistry, achieving approximately a 10% success rate of mRNA escape from intracellular degradation compartments inside T cells, which is substantially higher than the 1% to 2% efficiency observed with many other nanoparticle platforms.

The engineered nanoparticles were benchmarked against commercially available magnetic beads traditionally used for T cell stimulation in laboratory settings. Results demonstrated equivalent efficacy in T cell activation levels, but with the significant advantage that the nanoparticles advanced one step further by penetrating the cells to initiate genetic reprogramming. This dual functionality underscores the therapeutic promise of the technology, enabling both priming and modification of immune cells in a seamless process.

This pioneering research signifies a convergence of immunology and biomedical engineering disciplines at Johns Hopkins. By fusing knowledge from artificial immune cell development and polymer-based nanocarriers, the team has fashioned a streamlined immunotherapeutic tool with scalable manufacturing potential. Their goal is to expand this platform to refine targeting specificity, modulate the intensity of immune stimulation, and eventually translate it into human clinical applications for diseases driven by pathogenic B cells.

In recognition of its transformative potential, this research collaboration has secured over $40 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), enabling continued innovation and development of next-generation cellular engineering technologies. The funding will support fine-tuning of the nanoparticles, ensuring safety, efficacy, and versatility across a range of immune-related disorders.

As these biodegradable nanoparticles advance toward clinical trials, they hold the promise to revolutionize immunotherapy by providing an off-the-shelf, highly adaptable treatment modality. This approach could significantly reduce the financial and temporal burdens associated with conventional CAR-T therapies, while expanding patient access globally. By harnessing the immune system’s intrinsic power to heal from within, this technology represents a paradigm shift toward more precise, efficient, and personalized medicine.

In summary, Johns Hopkins’ innovative nanoparticle platform has successfully demonstrated in vivo engineering of immune T cells, leading to rapid and substantial depletion of disease-associated B cells. The modularity and simplicity of the design, combined with its intracellular delivery success, mark a vital step forward in immunotherapeutic technology. As the research continues to evolve, it offers hope for safer, more accessible treatments for autoimmune diseases and hematologic cancers, redefining the landscape of future immune-based interventions.

Subject of Research: Engineering Immune T Cells In Vivo Using Biodegradable Nanoparticles for Targeted Depletion of Pathogenic B Cells in Autoimmune Diseases and Blood Cancers

Article Title: Simplified Biodegradable Nanoparticles for In Vivo Engineering of T Cells to Target Autoimmune and Hematologic Diseases

News Publication Date: March 11, 2024

Web References: https://www.science.org/doi/10.1126/sciadv.adz1722

References: DOI: 10.1126/sciadv.adz1722

Image Credits: Manav Jain and Jordan Green, Johns Hopkins Medicine

Keywords

Nanoparticles, Immunotherapy, CAR-T cells, mRNA delivery, Biodegradable polymers, T cell engineering, Autoimmune diseases, Blood cancers, In vivo gene therapy, Immune modulation, Johns Hopkins Medicine, Nanomedicine

Biomedical engineer and computational biologist Dr. Steven Salzberg from Johns Hopkins University emphasizes the importance of scientific rigor and replication, noting, “It’s the nature of science to validate, confirm and reproduce findings.” Employing whole genome sequencing data organized within The Cancer Genome Atlas (TCGA), his team analyzed 5,734 samples spanning 25 different cancer types, accounting for both solid tumors and hematological malignancies in nearly equal proportions alongside matched normal tissue and blood controls. This enormous dataset allowed for a detailed and methodical re-assessment of microbial sequence presence in human cancers with unprecedented scope and precision.

The TCGA data consists of billions of short DNA fragments, known as ‘reads,’ which are sequences output by next-generation sequencing instruments. Originally gathered to identify mutations in human cancer genomes, these datasets inherently hold fragments of microbial DNA if present in the tumor tissue. Nevertheless, the accuracy of detecting such microbial sequences is complicated by the pervasive problem of contamination—artifacts introduced from laboratory reagents, environmental exposure, and sequencing platform residues. Dr. Salzberg’s team deployed sophisticated bioinformatics strategies designed to rigorously differentiate true microbial reads from contaminant noise, an endeavor fundamental to the new study’s reliability.

To accomplish this, researchers first meticulously filtered out human DNA sequences by mapping every read against two comprehensive human reference genomes: one assembled by the Telomere-to-Telomere (T2T) project, which provides an unprecedented level of completeness, and another from the Genome Reference Consortium. Despite the removal of human sequences, millions of reads initially thought to be microbial were identified as residual human DNA or contaminating sequences, underscoring the pervasive challenge contaminants pose in microbial mapping efforts.

Following this extensive cleaning process, approximately 0.35 percent of the total reads per sample remained as non-human, non-contaminant sequences. These were then compared against a vast database encompassing over 50,000 genomes spanning bacteria, viruses, fungi, and archaea. The final analysis found that microbial DNA constituted an average of merely 0.57 percent of total reads in solid tumor samples and 0.73 percent in blood cancers, percentages drastically lower than those reported by earlier investigations.

The study provides a direct comparison to a widely cited paper from five years prior published in Nature, which has since been retracted due to concerns over contamination. The previous Nature study reported microbial reads at an order of magnitude higher, with some samples containing up to 9,000 times more microbial sequences than observed by the Johns Hopkins team. Such discrepancies highlight the severe consequences of contamination in sequencing assays and stress the need for meticulous analytical standards.

Similarly, a 2022 study published in Cell identified vast quantities of fungal DNA across cancer samples—levels hundreds of times greater than those found by the Johns Hopkins group. Dr. Salzberg attributes these inflated estimates largely to contaminants, with yeast-like Saccharomyces cerevisiae, a known lab contaminant, appearing frequently in both past studies and the current analyses. Intriguingly, sequences of viruses infecting plant fungi, such as Rosellinia necatrix partitivirus 8, also appeared, signaling contamination from environmental sources unrelated to human pathology.

Despite detecting microbial DNA at lower levels, the Johns Hopkins researchers did confirm the presence of microbes with established links to human cancers, such as human papillomavirus (HPV), known for its role in cervical and certain head and neck cancers, Helicobacter pylori, implicated in stomach cancer, and bacterial species like Fusobacterium nucleatum and Bacteroides fragilis which have associations with gastrointestinal malignancies. This indicates that while the microbial burden may be smaller than previously suggested, bona fide microbial-cancer relationships remain scientifically valid and warrant further study.

Dr. Salzberg cautions that as the medical and scientific communities seek new diagnostic tools leveraging microbiome information to detect cancers at earlier stages, it is especially critical to ensure that findings attributing microbial presence to cancer are robust and reproducible. “Carefully documenting these associations with strict controls against contamination is essential,” he notes, highlighting the broader implications of the research for translational medicine and cancer diagnostics.

The Johns Hopkins team has made their data and analytical pipelines openly accessible through supplementary materials in Science Translational Medicine as well as on public repositories, fostering transparency and enabling other investigators to build upon or challenge their findings. Collaborators on the project include Jennifer Lu, Daniela Puiu, and Mahler Revsine, who contributed to the bioinformatics and computational analyses integral to the data validation efforts.

Funded by the National Institutes of Health, this study marks a critical recalibration in understanding the microbial compositions within cancer tissues and underscores the vital role of methodological rigor in next-generation sequencing studies. As the field moves forward, these findings invite a more cautious interpretation of the microbiome’s role in oncogenesis and highlight the ever-present challenges posed by contamination in high-throughput genomic data.

Subject of Research: Microbial DNA presence and its association with various human cancers.

Article Title: Not explicitly provided; inferred as “Reassessing Microbiome Presence in Human Cancers via Whole Genome Sequencing.”

News Publication Date: September 3, 2024.

Web References:

• Johns Hopkins Medicine news release
• Science Translational Medicine article DOI: 10.1126/scitranslmed.ads6335
• Supplemental data repository: https://zenodo.org/records/16544698

References:

• Previous Nature microbiome-cancer study (retracted)
• 2022 Cell fungal DNA study
• Johns Hopkins prior publication in mBio (2023)

Keywords: Cancer, microbiome, microbial DNA, contamination, sequencing, whole genome sequencing, next-generation sequencing, HPV, Helicobacter pylori, Fusobacterium nucleatum, Bacteroides fragilis, Saccharomyces cerevisiae

The concept of viral latency in HIV infection has long been a significant barrier to curing the disease. HIV integrates its genetic material into host immune cells, particularly CD4+ T cells, where it can lie dormant for extended periods. During latency, the virus does not produce new copies of itself, evading both immune detection and antiviral drugs. The Johns Hopkins team, led by Dr. Fabio Romerio, focused on AST, a molecular transcript encoded by the HIV genome on the strand opposite to the one that produces viral proteins. AST appears to be part of a naturally occurring regulatory mechanism that restricts viral gene expression and maintains the virus in a silent state.

In their recent study, researchers genetically engineered HIV-infected CD4+ T cells to overexpress AST, adding a genetic element designed to amplify AST production within the cells. This manipulation led to a significant decline in viral transcriptional activity. They used green fluorescent protein (GFP) as a surrogate marker for HIV gene expression, observing that cells with elevated AST levels exhibited nearly undetectable GFP fluorescence, indicating deep viral dormancy. This finding underscores AST’s potential as a molecular switch to silence viral replication robustly and sustainably.

Further molecular analysis focused on dissecting the structure-function relationships of the AST molecule. Utilizing advanced laser-based cytometry techniques, the team identified specific regions of AST critical for its ability to bind and recruit host proteins that enforce viral silencing. By creating a series of targeted mutations within the AST sequence, the researchers delineated domains essential for initiating and maintaining latency. These insights are pivotal for guiding the design of gene therapies that could specifically enhance the virus’s natural latency mechanisms.

Crucially, the study extended beyond laboratory-grown cell lines to examine the behavior of AST in CD4+ T cells derived from individuals living with HIV. These cells were transiently transfected with DNA encoding AST through a method that permeabilizes cell membranes, enabling direct delivery of genetic material. This approach proved successful in inducing viral latency, with HIV remaining dormant for at least four days post-treatment. The transient nature of AST expression, which declined as the introduced DNA fragmented, highlights the need for stable gene therapy methods to sustain this state in patients.

The biomedical significance of this research is heightened by the limitations of current antiretroviral therapies (ART). While ART effectively suppresses active viral replication, it does not eradicate the latent reservoir. Patients must adhere to lifelong medication regimens, which can lead to cumulative side effects and the risk of viral rebound if interrupted. The Johns Hopkins team’s vision is to develop a single-dose gene therapy strategy that boosts intrinsic viral latency pathways through AST, offering a durable functional cure and drastically reducing treatment burdens.

Mechanistically, the antisense transcript likely modulates chromatin remodeling and recruits epigenetic regulators to the integrated viral genome. This suppresses transcription of viral genes, maintaining the genome in a repressed configuration that prevents reactivation. Understanding this precise interplay between viral RNA transcripts and host cell machinery opens new doors for targeting HIV reservoirs that have traditionally been resistant to conventional therapies.

The research, which was funded primarily by the National Institutes of Health and supported by the American Foundation for AIDS Research, involved multidisciplinary collaboration among molecular biologists, immunologists, and clinicians. Alongside Drs. Fabio Romerio and Rui Li at Johns Hopkins, scientists from Massachusetts General Hospital and George Mason University contributed to refining the experimental approaches and validating the findings in patient-derived cells.

Looking forward, the integration of AST-based gene therapies into clinical practice will require overcoming significant hurdles, including efficient and safe delivery of genetic materials to patient immune cells, long-term expression and stability of AST, and comprehensive assessment of potential off-target effects. However, the proof-of-concept established by this study marks a critical step toward a new class of therapeutics aimed at functionally curing HIV by harnessing its own genetic machinery.

The broader impact of these findings also resonates with the global burden of HIV/AIDS, where nearly 40 million people live with the virus, and hundreds of thousands succumb each year despite the availability of effective therapies. A gene therapy that induces a permanent dormant state could transform public health strategies, reduce transmission rates, and alleviate the financial and societal costs associated with chronic antiviral medication.

In conclusion, the innovative exploitation of the HIV-encoded antisense transcript to enforce viral latency signifies a promising frontier in HIV research. By manipulating viral RNA to maintain the virus in a deep sleep, scientists are paving the way for transformative therapies that could one day liberate patients from the necessity of lifelong antiretroviral regimens. As this research progresses toward clinical translation, it holds the potential to redefine how we understand and ultimately manage HIV infection.

Subject of Research: Molecular mechanisms of HIV latency mediated by antisense transcript (AST) and gene therapy approaches to induce long-term viral dormancy.

Article Title: Untitled in source content (not provided).

News Publication Date: May 9 (year not specified, refers to journal publication date).

Web References:

• Science Advances article
• Johns Hopkins Medicine study page
• HIV statistics – HIV.gov
• WHO HIV/AIDS data

References: See the Science Advances publication and prior studies by Johns Hopkins team.

Keywords: HIV latency, antisense transcript, viral dormancy, gene therapy, CD4+ T cells, viral transcription, HIV replication suppression, molecular biology, viral reservoirs

The study, conducted on the immune systems of genetically modified mice, offers fresh insights into the complex signaling pathways that govern T cell activation. QRICH1 has been identified as a crucial component in the signaling pathway of CD8+ T cells, which play a significant role in the immune response by identifying and destroying infected or cancerous cells. The researchers discovered that QRICH1 functions as a partial brake within this system, meaning that its regulation could lead to innovative strategies for both enhancing immune responses against cancer and inhibiting excessive T cell activity in autoimmune diseases.

Immunotherapy has emerged as a powerful tool in the treatment of various cancers. By harnessing the body’s natural immune system, these treatments can expedite the death of tumor cells or suppress autoimmune responses that damage healthy tissue. The quest for new drug targets like QRICH1 is therefore a critical avenue of research aimed at making immunotherapy safer and more effective for patients suffering from these serious conditions.

According to Joel Pomerantz, Ph.D., senior author of the study and associate professor at Johns Hopkins University School of Medicine, the discovery of QRICH1 as a modulator for T cell activation opens up exciting possibilities for drug development. The researchers are optimistic that by targeting this protein, they can enhance the efficacy of immunotherapies and develop new treatments that better manage immune-related diseases.

To investigate the role of QRICH1 in T cell signaling, the team genetically engineered mice to lack this particular protein. Their experiments demonstrated the indispensable role of QRICH1 in facilitating T cell signaling, as T cells extracted from these QRICH1-deficient mice displayed heightened activity in response to signals mimicking cancerous or infected cells. The increased T cell activity observed correlates with QRICH1’s role as a regulatory element that tempers T cell activation, suggesting that pharmaceutical interventions could be designed to manipulate QRICH1’s functioning.

The implications of this research extend beyond theoretical applications. In the context of various cancers, QRICH1 could be strategically targeted to boost T cell activation, thereby improving responses against malignant cells. Conversely, in cases where T cells are overactive—such as in autoimmune diseases and certain blood cancers like leukemia and lymphoma—QRICH1’s inhibitory role could provide a means to downregulate T cell activity and alleviate disease progression.

Further investigations revealed that mice lacking QRICH1 exhibited a significantly stronger immune response when exposed to listeria monocytogenes, a bacterium responsible for foodborne infections. This natural infection model indicates that T cells can be overly activated in the absence of QRICH1, demonstrating its vital function as a regulatory protein in immune responses. Such findings are crucial in understanding how the immune system can be manipulated for therapeutic benefits.

Moving forward, the researchers plan to explore how T cells engineered without QRICH1 respond to cancerous cells, intending to unravel the intricate mechanisms of immune regulation and cellular communication in the context of malignancies. This avenue of research promises to yield valuable insights into the potential for QRICH1-targeted therapies to elevate the immune system’s effectiveness in combatting cancer.

This pioneering study has been supported by funding from the National Institutes of Health and represents a significant step forward in the search for new cancer treatments. It highlights the importance of understanding molecular interactions in the immune system and their potential to be translated into clinical applications that transform patient outcomes.

By delineating the role of QRICH1 in regulating T cell activation, this research paves the way for further investigation into the mechanistic underpinnings of immune responses. As scientists uncover the complexities of immune signaling, they move closer to designing targeted therapies that leverage the body’s inherent defenses against disease.

QRICH1 stands out not only for its biological significance but also for its therapeutic potential. As researchers work to identify and engineer drugs that can modulate this protein’s activity, they are poised to create innovative treatments that harness the power of immunotherapy with increased specificity and reduced risk.

In conclusion, the discovery of QRICH1’s role in T cell receptor signaling presents an exciting opportunity for advancing immunotherapy. This research exemplifies the vital intersection between fundamental science and clinical application, foreshadowing a future where precision medicine can fine-tune immune responses to better treat cancer and autoimmune diseases.

With ongoing studies and the promise of QRICH1-targeted therapeutics, the scientific community remains hopeful about the possibilities of reshaping how diseases are treated, driven by an understanding of the intricate biology of immune system regulation. As the field evolves, the potential for QRICH1 in therapeutic applications could lead to breakthroughs that change the landscape of treatment for millions of patients worldwide.

Subject of Research: The Role of QRICH1 in T Cell Activation and Potential Applications in Immunotherapy
Article Title: New Insights into QRICH1: A Key Regulator of T Cell Activation with Therapeutic Implications
News Publication Date: March 14, 2023
Web References: Science Immunology
References: National Institutes of Health (RO1AI43053, F31CA254167 and T32GM007445)
Image Credits: Nicole M. Carter

Keywords: QRICH1, T cell activation, immunotherapy, cancer treatment, autoimmune diseases, immune regulation, signaling pathways, CD8+ T cells, drug development